Last edition
News about Global Pharma
AbbVie Announces Completion of Acquisition of Capstan Therapeutics
AbbVie has completed its acquisition of Capstan Therapeutics, bringing onboard Capstan’s tLNP platform and lead asset CPTX2309 to advance next-generation in vivo CAR-T therapies for autoimmune diseases.
Global Pharma | 20/08/2025 | By Mrinmoy Dey | 306
XtalPi has signed an MoU with South Korea’s Dong-A ST to co-develop novel therapies for immunological and inflammatory diseases using its AI-driven, automated drug discovery platform.
Global Pharma | 20/08/2025 | By Mrinmoy Dey | 126
Extrovis AG, Dr. Reddy's Partner to Roll Out CARAC 0.5 Percent Generic in US Market
Extrovis AG and Dr. Reddy's Laboratories have announced the launch of Fluorouracil Cream, 0.5 percent, an authorised generic and therapeutic equivalent of Carac (fluorouracil cream) 0.5 percent, in the US market.
Global Pharma | 19/08/2025 | By Dineshwori | 302
Indian contract development and manufacturing organisations (CDMOs) and CRDMOs are poised for improved profitability and healthier credit profiles, driven by a shifting supply chain landscape in the United States.
Global Pharma | 19/08/2025 | By Darshana | 259
Avixgen, US Biotech Firm Ink USD 360 Mn Deal for Next-Gen Drug Delivery Platform
Avixgen has signed a licensing-out agreement worth approximately USD 360 million with a US biotechnology company for its next-generation drug delivery platform, ACP (Advanced Cell Penetrating Peptide).
Global Pharma | 19/08/2025 | By Dineshwori | 279
Skyhawk Therapeutics has entered a strategic research collaboration worth over USD 2 billion with Merck KGaA, Darmstadt, Germany to develop novel RNA-targeting small molecules for neurological disorders.
Global Pharma | 19/08/2025 | By Mrinmoy Dey | 243
Glenmark Pharmaceuticals to Launch Micafungin for Injection in US in September 2025
Glenmark Pharmaceuticals Inc., USA has announced the September 2025 launch of Micafungin for Injection USP, 50 mg and 100 mg vials, the bioequivalent of Astellas Pharma’s Mycamine.
Global Pharma | 19/08/2025 | By Mrinmoy Dey | 256
Remegen Partners with Santen To Commercialise RC28-E in Greater China and Asian Countries
RemeGen, a leading Chinese biopharmaceutical company, has entered into an exclusive licensing agreement for the ophthalmic innovative drug RC28-E with Santen China, a wholly-owned subsidiary of Santen Pharmaceutical.
Global Pharma | 19/08/2025 | By Dineshwori | 353
Atezolizumab will be provided by Genentech for use in Pilatus’ clinical research; PLT012 is Pilatus’ immunomodulatory candidate.
Global Pharma | 18/08/2025 | By Abha | 207
Marksans Pharma's UK Subsidiary Relonchem Secures Multiple MHRA Approvals
Marksans Pharma's wholly owned UK subsidiary, Relonchem Ltd., has received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) for Metformin Hydrochloride Relonchem Prolonged Release Tablets in three strengths—500 mg, 750 mg, and 1000 mg.
Global Pharma | 18/08/2025 | By Dineshwori | 475
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy